KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash & Equivalents (2016 - 2026)

Pfizer has reported Cash & Equivalents over the past 18 years, most recently at $1.7 billion for Q1 2026.

  • Quarterly Cash & Equivalents rose 19.09% to $1.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Mar 2026, up 19.09% year-over-year, with the annual reading at $1.1 billion for FY2025, 9.49% up from the prior year.
  • Cash & Equivalents was $1.7 billion for Q1 2026 at Pfizer, up from $1.1 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $3.1 billion in Q4 2023 and troughed at $416.0 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $1.4 billion (2025), against an average of $1.6 billion.
  • Year-over-year, Cash & Equivalents crashed 78.6% in 2022 and then skyrocketed 585.82% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $416.0 million in 2022, then skyrocketed by 585.82% to $2.9 billion in 2023, then plummeted by 63.44% to $1.0 billion in 2024, then rose by 9.49% to $1.1 billion in 2025, then soared by 49.12% to $1.7 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Cash & Equivalents are $1.7 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.3 billion (Q3 2025).